MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
PRQR - ProQR Therapeutics N.V
$4.71
0.36(8.16%)8:38:31 PM 2/24/2021
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Stock news

    02/16/2021PRQR
    ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that the Company will host an Expert Perspectives call on February 22, 2021 at 12:00pm EST. The call will feature a discussion between Aniz Girach, MD, Chief Medical Officer of ProQR Therapeutics and Paul Yang, MD, PhD about...

    01/21/2021PRQR
    2 “Strong Buy” Penny Stocks That Could See Outsized Gains

    Well, it’s official. Joe Biden is now President, and he’ll be backed – at least for the short term – by Democratic majorities in both Houses of Congress. Wall Street is taking the measure of the new Administration, and sees, among its first moves, a boost in fiscal stimulus that is likely to goose consumer spending, bump corporate profits, and provide general economic support in the first half of 2021. Covering the situation for Goldman Sachs is investment strategist David Kostin, who is bullish...

    01/18/2021PRQR
    Is ProQR Therapeutics (NASDAQ:PRQR) Using Debt In A Risky Way?

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

    01/7/2021PRQR
    ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10

    * Top-line results expected H1 2022 * Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindnessLEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced it has completed patient enrollment in its Pha...

    12/18/2020PRQR
    ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present during a fireside chat at the upcoming HC Wainwright Virtual BIOCONNECT 2021 Conference. A webcast of the presentation will be accessible from the “Investors & Media” section of ProQR’s w...

    12/1/2020PRQR
    Hedge Funds Are Selling ProQR Therapeutics NV (PRQR)

    We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of ProQR Therapeutics NV (NASDAQ:PRQR) based on that […]

    11/18/2020PRQR
    ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present during a fireside chat at the upcoming 3rd Annual Evercore ISI Virtual HealthCONx Conference. The presentation will be webcast live on December 2, 2020 at 3:55pm EST. The live and archiv...

    11/17/2020PRQR
    How Is ProQR Therapeutics' (NASDAQ:PRQR) CEO Paid Relative To Peers?

    Daniel de Boer has been the CEO of ProQR Therapeutics N.V. (NASDAQ:PRQR) since 2012, and this article will examine the...

    11/16/2020PRQR
    ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates

    ProQR (PRQR) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?